C
Celldex Therapeutics Inc.
Biotechnology: In Vitro & In Vivo Diagnostic Substances company
Key Metrics of Celldex Therapeutics Inc.
Revenue$6.9M▲ 192.0% YoYFY 2023
Operating income−$155M▼ 34.1% YoY
Net profit−$141M▼ 25.9% YoY
Shareholders' equity$429M
Market cap$2.4BCLDX · $30.15
Competitors10identified
About Celldex Therapeutics Inc.
Sectors
Company details
- Listed
- Nasdaq: CLDX
Operational Areas of Celldex Therapeutics Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameCelldex Therapeutics Inc.
TickerCLDX
ExchangeNasdaq
CountryUnited States
SEC CIK0000744218
Listed since—
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
CLDX · Nasdaq · SEC CIK 0000744218
Last price · 29 Oct 2026
$30.15
+2.20%
Market cap$2.4B
P/E—On FY 2023 diluted EPS
Volume746,597
SectorHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances
Country · IPOUnited States
CLDX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Celldex Therapeutics Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.